Year: 2025

DynaCAD urology with advanced annotationUroNav cart with advanced annotation optionUroNav with advanced annotationJuly 23, 2025 Supporting prostate cancer diagnosis with more precise guidance for clinicians, offering better patient care Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a major advancement in image-guided navigation for prostate cancer care with the FDA 510(k) clearance of the latest Philips UroNav version. The system includes a new advanced annotation [1] workflow that supports clinicians during focal therapy procedures, helping deliver more precise, minimally invasive care. This release comes at a time of increasing need for innovation in prostate cancer care. Prostate cancer remains the most commonly diagnosed solid tumor...

Vancouver, Canada, July 23, 2025 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the “Company”), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced the successful completion of site initiation at Tel Aviv Sourasky Medical Center (TASMC) for its Phase I/IIa clinical trial evaluating CMND-100, a proprietary oral drug candidate for Alcohol Use Disorder (AUD). This milestone advances Clearmind’s mission to transform treatment for the global epidemic of AUD, which affects millions and accounts for 2.6 million deaths annually. The Phase I/IIa trial, already underway at prestigious sites, including Yale School of Medicine and Johns Hopkins University in the United...

PH1 modulates RNA splicing, causing cancer cell death while activating the immune system to attack cancer throughout the body Company advancing pipeline of ADCs using PH1 payload across both Trop2 and an undisclosed target Emerging new preclinical data on impact of PH1 payload against a key oncogenic driver is expected before year-end BOSTON and LONDON, July 23, 2025 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today reiterated its commitment to ongoing research to better understand the multiple effects of its novel spliceosome modulator, PH1, having demonstrated it may also act to inhibit key drivers in cancer tumors. “We are excited to build on the scientific data already established...

LOS ANGELES, July 23, 2025 (GLOBE NEWSWIRE) — Dave Inc. (“Dave” or the “Company”) (Nasdaq: DAVE), one of the nation’s leading neobanks, will host a conference call on Wednesday, August 6, 2025 at 8:30 a.m. Eastern time to discuss its financial results for the second quarter ended June 30, 2025. The Company’s results will be reported in a press release on the same day, prior to the conference call. Dave management will host the conference call, followed by a question-and-answer period. The conference call details are as follows: Date: Wednesday, August 6, 2025Time: 8:30 a.m. Eastern timeToll-free dial-in number: (866) 652-5200International dial-in number: (412) 317-6060Webcast: link The conference call will also be available for replay in the Events section of the Company’s website, along with the transcript, at https://investors.dave.com. If...

Key HighlightsStrategic Capitalization: Matador has executed a Purchase Agreement for a USD $100 million secured convertible note facility (the “Facility”) with ATW Partners, featuring an initial USD $10.5 million tranche.Exclusive Use of Proceeds: Proceeds are earmarked for purchasing Bitcoin as part of Matador’s treasury allocation strategy, with the intention of increasing long-term Bitcoin-per-share (BPS).Institutional Partnership: ATW Partners—an institutional investor known for structuring growth-stage financings—brings both capital and strategic depth to Matador’s Bitcoin ecosystem vision. Flexible, Equity-Aligned Structure: The secured convertible notes provide minimally dilutive, price-adaptive funding that converts at market-aligned prices.Accelerates Treasury Plan: Supports Matador’s roadmap to acquire up to 1,000 BTC...

Video webcast now available on-demand MINNEAPOLIS, July 23, 2025 (GLOBE NEWSWIRE) — Nuwellis, Inc., today announced that John Erb, President and Chief Executive Officer of Nuwellis, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. For the event, Mr. Erb dove deeper into his dedication to the Company, how he got to where he is today, and provided insight into why he is passionate about the Company’s programs in development. The on-demand video webcast is now available on the www.virtualinvestorco.com as well as the Newsroom page under the Investors section of the Company’s website (www.nuwellis.com). About Nuwellis Nuwellis, Inc. (Nasdaq: NUWE) is a medical device company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and...